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Abstract Modelling human diseases in in vitro systems is
undisputedly an invaluable research tool, yet there are
many limitations. Some of those limitations have been
overcome through the introduction of organoid culture
systems, which have revolutionised colorectal cancer re-
search and enabled an array of new experimental tech-
niques. This 3D system models the physiology, shape,
dynamics and cell make-up of the intestinal epithelium
producing a relevant and highly adaptable model system.
The increased functional relevance of this model com-
pared to the use of 2D cancer cell lines makes it an in-
valuable tool for both basic and translational research. As
the limitations of this system are being overcome to make
high-throughput assays possible, it is clear that organoids
are becoming a mainstay of colorectal cancer research.
This review aims to explore the advantages and limita-
tions of this system and discusses the future directions
enabled by this model.
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Introduction
Colorectal cancer (CRC) is the fourth most common cancer
type in the UK, but the second most common cause of death
by cancer. Experimental systems in which the development of
CRC can be modelled crucially underpin many advances in
the development of novel therapies for CRC. However, de-
spite increased understanding of the causes of CRC, the dis-
ease modelling systems available to researchers still remain
limited.
The role of intestinal stem cells (ISCs) as the cell of origin
of intestinal cancer has been well described and generally
accepted [1], with the knowledge that it is mutations within
the crypt base columnar (CBC) cells which drives initiation of
tumourigenesis. In order to gain insight into the earliest stages
of tumourigenesis, it is therefore necessary to study this pop-
ulation of cells.
Interestingly, there is still much dispute about which mark-
er genes can reliably identify the CBC population [2] and the
way in which stem cell dynamics contribute to CRC. The
development of robust 3D culture systems from intestinal
stem cells for the growth and maintenance of both normal
and tumour tissue from intestinal and colonic samples of both
mouse and human origin is already revolutionising the world
of CRC research.
In 1992, a system for culturing 3D rat intestinal organoids
was published [3, 4]. Despite providing a more functionally
relevant culture system than previously available through the
use of immortalised cell lines, the impact of this method was
limited by the transient nature of the ISC divisions it enabled,
resulting in established cultures only surviving for up to
1 month. In 2009, Sato et al. published a robust method which
enabled the production of self-renewing intestinal organoids
which could be expanded indefinitely [5]. The organoid cul-
ture method proposed by Sato in 2009 uses matrigel as a 3D
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matrix in which to embed either intestinal crypts or FAC-
sorted Lgr5+ intestinal epithelium cells [5]. This method was
soon optimised to enable the production of organoids from
murine and human colon and colorectal adenoma tissue as
well as from human colonic stem cells [6, 7].
In this organoid culture system, the epithelial cells are em-
bedded within matrigel which supports growth within a 3D
matrix, and the laminin-rich nature of matrigel mimics the
microenvironment of the crypt base in vivo [8]. In addition,
this system requires the provision of culture medium including
growth factor supplements designed to support intestinal crypt
growth and maintain the ISC population. Noggin (an inhibitor
of the bone morphogenetic protein (BMP) signalling path-
way) is added to the culture medium as BMP signalling has
been shown to inhibit intestinal stem cell self-renewal [9].
Epidermal growth factor (EGF) is another key constituent of
the growth medium due to its association with proliferation
within the intestinal epithelium [10]. R-spondin is an addition
to the culture medium required when growing organoids from
normal or non-Wnt-activated intestinal epithelium. R-spon
dins are activators of the Wnt-signalling pathway which act
specifically through the Lgr receptors (such as the ISC marker
Lgr5) and thereby specifically upregulate Wnt-signalling
within the ISC population, as well as driving crypt hyperplasia
in vivo [11, 12]. In addition to these growth factors, the Rho-
kinase inhibitor Y-27632 is required for culturing single cells,
as it has been shown to inhibit anoikis in isolated embryonic
stem cells [13]. Interestingly, organoids grown from human
CRC samples often grow more successfully in the absence of
niche factors, dependent on the mutational background of the
samples and which signalling pathways are activated [14••,
15••].
This method not only produces 3D organoids, but those
organoids have all of the epithelial cell types observed in the
original system, with intestinal organoids even maintaining a
functionally discrete Bcrypt^ region and a conserved migra-
tion of the differentiated cells along a crypt-villus axis. This
makes the organoid system a more functionally relevant mod-
el to in vivo response than traditional 2D culture methods, and
provides the effective Bmissing link^ for researchers between
in vitro and in vivo studies.
Modelling disease in vitro has many advantages over the
use of animals in research. Aside from the obvious ethical
advantage, in vitro modelling of colorectal cancer enables
genetic alterations to be made easily, quickly and relatively
cheaply. However, traditional 2D culture techniques have held
numerous disadvantages due to cell homology and lack of
cell/cell interactions. The use of 3D culture techniques such
as those described above opens a brand new range of possi-
bilities for modelling colorectal cancer, enabling the exploita-
tion of a brand new toolkit in researching this disease. Broadly
speaking, CRC research can be subdivided into two main
categories: basic research and translational research; and the
use of organoids as a model system is already proving its
utility in both areas (Fig. 1).
BASIC: Stem Cell Assay
Despite ISCs being thought to be the cell-of-origin of CRC
[1], the difficulty of quantifying the ISC population within
mouse models has been a limiting factor in many areas of
CRC research. ISC markers can be used to visualise the ISC
population although there is controversy over the most appro-
priate markers to use [2]. One of the major hurdles is that the
majority of ISC markers, including the most commonly used
marker Lgr5, are themselves Wnt targets. As much CRC re-
search relies on the mis-regulation of Wnt signalling to mimic
the human condition, this may have an impact on the expres-
sion levels of these markers without directly affecting the
functionality of the ISC population. In this way, the use of
intestinal organoids can be exploited for the study of the ISC
population.
Themain hallmarks of adult stem cells include the ability to
self-renew as well as the potency to divide to produce the
complete range of different cell lineages found within a tissue.
The ability to form organoids in culture was first used as an
assessment of the adult stem cell population within the ner-
vous system [16], but has since been used as a stem cell assay
within a variety of different tissues, including pancreas [17],
mammary [18] and skin [19]. Given that it is known that
Lgr5+ intestinal epithelial cells are the only cell type capable
of efficiently forming differentiated organoids in culture, it is
possible to apply the same methodology to the intestine [20,
21]. This has enabled a functional readout of Bstemness^with-
in the gut through the determination of organoid formation
efficiency and organoid self-renewal efficiency. Interestingly,
it was the ability to form organoids in culture which enabled
the identification of human colonic stem cell population as the
subset of colonic epithelial cells which express high surface
levels of Ephb2 [7]. Thus, adaptation of different 3D culture
Fig. 1 Organoid culture can be used as a model system for both basic and
translational research
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systems is able to functionally assess the stem cell capacity of
different cell populations.
BASIC: Ease of Genetic Manipulation
The development of CRC is a multistep process, with the
requirement for mutations in several different genes for the
progression of benign polyp to malignant adenocarcinoma
[22]. Modelling this process has previously proved to be a
challenge in vivo, where temporal control of genetic muta-
tions is possible through the use of techniques such as Cre-
LoxP, but sequential deletion of a series of genes is often
impractical. This has led to a knowledge gap as to the impor-
tance of the series step-wise mutations observed in the devel-
opment of the disease. The use of the Cre-LoxP technology
has been successfully applied to organoid culture to increase
understanding of tumour progression [23•], but given that
these systems still require the establishment of the organoids
from a pre-existing in vivo model, they are limited by the
requirement for breeding mice of the correct genotype for
experimentation, which is not only time consuming and ex-
pensive but also has ethical implications.
Genetic manipulation of intestinal and colonic organoids
for the purposes of CRC research using siRNA has been ex-
plored and is possible [24], but is limited by technical diffi-
culty and inefficiency of transfection in 3D.
The recent advances in genetic engineering as a result of
the development of the clustered regularly interspaced short
palindromic repeats-CRISPR-associated 9 (CRISPR-Cas9)
system are ideal for use in an organoid system. The
CRISPR-Cas9 system utilises a prokaryotic adaptive immune
system to enable the controlled replacement of sections of
genes of interest with specific and pre-designed gene muta-
tions in live cells with a low rate of off-target mutations [25].
The use of CRISPR-Cas9 technology in cancer biology is
reviewed in detail elsewhere [26]. CRISPR-Cas9 is already
beginning to revolutionise the way in which organoid culture
can be used for CRC research. Matano et al. used the
CRISPR-Cas9 method to genetically engineer organoids de-
rived from normal human intestinal samples in an attempt to
recreate the sequential establishment of driver mutations ob-
served in the development of CRC [14••]. Interestingly, the
successful introduction of each of the mutations (APC,
SMAD4, TP53, KRAS and PIK3CA) was selectable by alter-
ations to niche factors in the culture media (removal of Wnt/
Rspo, noggin, nutlin3- and MDM2 inhibitor, EGF, and the
addition of a Mek inhibitor, respectively). This method of
selection for successfully engineered cells is not reliant on
the use of antibiotics. Furthermore, these genetically modified
organoids recapitulate the independency from niche factors
that is observed in human CRC organoids, supporting its role
as a model system.
This model was further exploited to explore the role of
these mutations in invasion via the implantation of the genet-
ically engineered organoids under the kidney subcapsule of
mice [14••]. One of the major complications in treating CRC
is metastasis to the liver, which reduces survival rates dramat-
ically; however, understanding of the mutations which control
invasion and metastasis is limited by the lack of an accurate
model. Traditionally, these processes are difficult to investi-
gate in mice, as tumour burden often results in death prior to
metastasis. However, using the organoid method coupled with
CRISPR-Cas9 technology to recapitulate tumour progression
in culture, engineered organoids were successfully implanted
into mice under the kidney subcapsule to observe which CRC
driver mutations were essential for invasion and metastasis
[14••]. Interestingly, it was observed that despite containing
all driver mutations associated with tumour progression, the
engineered organoids did not form invasive tumours or
metastasise like the organoids derived from human CRC sam-
ples. This research implicates the importance of other factors
such as genomic instability in invasive behaviour and would
not have been possible without the use of the organoid system
and the flexibility of genetic manipulation that it enables.
BASIC: Co-Culture
One of the main advantages of using the organoid culture
system over in vivo models for studying CRC is the ability
to study the role of genetic mutations within the epithelium
whilst removed from the range of variables such as stromal
interactions and immune response. However, although this
enables the examination of tumour/intestinal response to a
range of genetic mutations, it is limited by lacking the com-
plexity of interactions which are observed in vivo. In order to
study the impact of different biological systems on the intes-
tinal epithelium in a controlled environment, co-culture can be
used. Over the recent years, there has been a drive for the
modification of culture conditions to enable the co-culture of
organoids from either intestinal or colorectal adenoma origin
with a variety of different cell types including lymphocytes,
nerves and fibroblasts [27–29]. These techniques, which vary
from subtle alterations of current techniques [27, 29] to the use
of well inserts [28], offer the opportunity to explore areas of
CRC research that have until now been inaccessible.
TRANSLATIONAL: Drug Assays
One of the greatest advantages of in vitro work over in vivo
work is the ability to perform large-scale drug assays with
relative ease and equally minimising the requirement for the
use of animals for research. Previously, 2D cell culture has
enable dramatic advances in drug screening for potential che-
motherapeutics but was limited by the lack of cellular hetero-
geneity and cell/cell interactions observed in vivo, making
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results potentially unreliable. The use of immortalised cell
lines in order to assess drug efficacy is in many ways limited,
with nearly 95% of the drugs which are found to have activity
in 2D cell cultures failing to reach clinical trial [30]. It has
been shown that intestinal crypt organoids are more accurate
at predicting the apoptotic response to 5-FU in the intestinal
epithelium ofmouse models than either of the commonly used
CRC cell lines Caco-2 or MC38 [31•]. In addition to this, it
has been shown that 3D spheroids formed from pancreatic
ductal adenocarcinoma develop chemoresistance in a more
physiologically relevant manner than equivalent 2D culture
[32]. As the development of chemoresistance is an important
limiting factor in the utility of pharmacological intervention in
CRC patients, this system may also provide a more function-
ally relevant model for CRC research. It is thought that 3D cell
cultures provides a more accurate model than 2D cell culture
because physical forces and spatial interactions between cells
play an important role in many cellular signalling pathways
[33].
Using ex vivo 3D primary culture as opposed to long-term
cultured immortalised cell lines has advantages seen from
many angles. In order to develop effective chemotherapeutics,
the pharmaceutical industry must investigate two main areas:
the efficacy of the drug at inducing apoptosis within tumour
cells and the toxicity of the drug to untransformed cells. As
one of the most common side effects of most chemotherapeu-
tic treatments is gut toxicity, this is particularly important in
the field of CRC research. In vitro modelling of both tumour
and normal intestinal epithelium is frequently performed using
the same system: transformed cell lines, making it difficult to
differentiate between positive drug effect and negative side
effects. The use of organoids enables the direct comparison
between response in tumour spheroids and response in normal
intestinal epithelial organoids, leading to a more informative
readout of drug efficacy.
Through the use of more functionally relevant cell culture
systems such as organoid culture, the efficacy of potential
chemotherapeutics suitable for use in CRC patients can be
explored prior to animal trials. This not only increases time
efficiency but it also enables the abandonment of ineffective
drugs prior to animal trials, resulting in a reduction in the use
of animal models. Another major advantage of using this
model system for drug assays is that organoids can be grown
in a 96-well and even 384-well format. This enables multiple
replicates using a wide range of samples and concentrations
whilst only using low volumes of potentially expensive and
difficult to acquire drugs.
One of the hurdles which is being overcome to enable the
use of organoid culture in medium to high throughput drug
studies is the issue of quantification. When healthy, organoids
present a closed system with a clean, light appearance with
clear epithelial integrity. However, when there is an increased
number of dead or dying cells within the organoid, the outer
surface is disrupted, displaying more loosely packed, often
smaller cells and an overall darker and less uniform appear-
ance, see Table 1. These Bdisrupted^ organoids have been
identified as representative of increased cell death [31•], but
the difficulty remained with quantification. In order to count
live/dead organoids in response to drug treatment, it was nec-
essary to rely on manual observations using brightfield mi-
croscopy, a method which is not only labour intensive but also
susceptible to inherent variations which arise from non-
automated systems. One common route for quantifying cell
death in traditional cell culture systems is through the use of
Table 1 Identification of living wild-type intestinal organoids through defined morphological features
Healthy/viable Disrupted/non-viable
Brightfield microscopy
Physical attributes Closed system with epithelial integrity
Ordered, tightly packed cells
Defined crypt protrusions
Identifiable luminal region
Absence of defined edge
Disordered, smaller, diffuse cells
No obvious structural elements
Dark central region
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MTT staining, whereby viable cells convert MTT into intra-
cellular formazan, a purple dye detectable by spectro pho-
tometry once solubilised using DMSO. As the 3D matrix in
which the organoids are embedded (matrigel) is not soluble in
DMSO, this technique had to be adapted for use in this sys-
tem, by incorporating a 2 % SDS step prior to DMSO expo-
sure in order to solubilise the matrigel [31•]. In addition to the
quantification of cell death, drug efficacy can be assessed by
measuring changes in cell viability. Commercially available
reagents, such as CellTiter-Glo® and PrestoBlue®, have been
widely used to assess metabolic activity and have been used
with success in 3D organoid culture. CellTiter-Glo® is capable
of quantifying ATP levels in a one-step end-point lumines-
cence assay, whilst PrestoBlue® changes colour to become
fluorescent in the presence of the reducing cytosol associated
with living cells. One advantage of PrestoBlue® is that it does
not require the disruption of the cells and so can be used as a
live-cell assay, enabling re-use of the organoids.
Although these methods of assessing drug efficacy are use-
ful, they are limited to assessing cell viability and do not
assess other changes within the organoids. The structural com-
plexity of organoids is an element of challenge not present
when using 2D cell culture. For example, are the number of
crypt-like protrusions remaining constant whilst undergoing
treatment? Are the organoids smaller or larger? Are theymade
up of the same size cells? Each of these readouts may provide
important data on the potential utility of proposed chemother-
apeutic agents. In order to assess all of these many potential
phenotypic changes, companies such as OcellO can screen
384 well plates of organoids using confocal imaging and spe-
cially designed software and image analysis to provide phe-
notypic profiles based on more than 900 different parameters
[34, 35]. As these systems and techniques becomemore wide-
ly used, it is clear to see how high-throughput drug assays
using organoids will become quicker, simpler and more
informative.
TRANSLATIONAL: Patient-Derived Organoids
An additional advantage of using organoids over in vivo stud-
ies is the ability to produce patient-derived organoids, either
from tumour and tumour-associated normal tissue from pa-
tient biopsies, or from induced pluripotent stem (IPS) cells
[36].
Culture of organoids derived from patient biopsies enables
the thorough testing of a range of therapeutic compounds in a
patient-relevant model. Although it is impossible to say that
the organoids derived from these sources remain genetically
and physiologically identical to the primary source, Jung et al.
used comparative genomic hybridization analysis to conclude
that the genomes of colorectal cancer stem cells which were
cultured long term as 3D spheroids remained stable [7]. The
ability to test a range of chemotherapeutics on actual patient-
derived organoids could lead to patient-specific personalised
therapy. On a broader scale, production of a range of patient -
derived organoids from a variety of different genetic profiles
will enable the exploration of specialised drug treatment plans
post-biopsy, as well as enable genetic manipulation using
technologies such as CRISPR-Cas9 to isolate the genetic mu-
tations responsible for specific cancer phenotype [37].
The development of such a bank has already begun,
with the establishment of a Bliving organoid biobank^
of organoids derived from colorectal cancer patients
[38]. By storing organoids derived from both malignant
and normal tissue of the same patient, each sample has
its own perfect control. As part of this biobank, the
mutational signature of the original tumour biopsy and
the organoid lines was assessed and compared. This
enabled the analysis of drug response of groups of
organoids with similar driving mutations, to assess drug
utility. The large scale of this project meant that a high-
throughput system was essential, and so drug screening
systems similar to those previously used in 2D culture
were utilised in a robotic system [39]. As this organoid
bank grows, it is hoped that more associations between
gene mutations and drug response will present them-
selves, making personalised therapy a more attainable
goal for the treatment of CRC.
The growth of intestinal organoids from iPS cells yet
another development of this system which could have
huge impact on the world of CRC research [36]. By
taking somatic cells of patients with familial adenoma-
tous polyposis (FAP), producing iPS cells and directing
differentiation into intestinal organoids, a model of FAP
can easily be produced without the need for invasive
biopsy. This is already being achieved with other forms
of familial cancer [40] and could help aid the develop-
ment of preventative therapies.
Conclusions
Organoid culture is already making impacts on CRC
research, and as the technique becomes more widely
used, it is expected that it could provide the missing
link between cell culture and in vivo modelling of the
disease. By providing an easy-to-handle model in which
genotype and phenotype can be directly compared in a
short space of time, the use of organoid culture opens
up an array of different experimental techniques which
were previously not possible. However, in spite of the
great utility of this model, the challenges of organoid
culture should not be overlooked.
As previously mentioned, human CRC organoids
have varied requirements for niche factors dependent
on the pathways activated within the source tumour
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[14••, 15••]. As the growth factors which are added to
the culture medium are selected to drive the most
growth of patient-derived organoids, this may result in
a bias towards the outgrowth of a particular subclone
within the tumour, leading to differences in the genetic
background between the tumour in vivo and ex vivo.
The observation from Matano et al. that gene expression
changes in organoids compared to in vivo as a result of
progressive mutations was comparable, despite changes
to growth factor exposure in culture, indicates that niche
bias is not a problem in this system [14••]. However, it
has been noted that under normal culture conditions
(with all growth factors added), normal human colonic
organoids outcompete CRC organoids [38], leading to
the conclusion that some bias as a result of niche fac-
tors is possible, and must be considered when planning
experiments.
As with any in vitro system, there is always a poten-
tial for genetic drift away from the original sample dur-
ing long-term culturing and multiple passages. Despite
the observation that CRC organoids remain genetically
stable, there is no reason why organoids will not be at
the same risk of genetic drift as 2D cell culture [41]. As
patient-derived CRC organoids come from frequently
genetically unstable and heterogeneous tumours, there
must remain the possibility of genetic divergence from
the original tumour. However, this risk can be reduced
by limiting culture time and minimising passage num
ber.
As with any model system, there are always limita-
tions, and differences between the response of intestinal
epithelium in vitro and in vivo are inevitable due to the
absence of other cell types within organoid culture. For
example, the absence of paneth cell-produced Wnts is
tolerated in vivo, but not in organoid culture [42].
However, as was seen by the differences in metastatic
potential between organoids genetically engineered to
contain major driver mutations and organoids from
genomically unstable CRC tumour samples [14••], these
differences can hugely benefit our understanding of tu-
mour development.
In spite of these potential differences, indeed often
because of them, the utility of 3D organoid culture as
a model for CRC research and the impact that this sys-
tem is having on the field is clear.
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